Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Pipeline Review, H2 2017’, provides in depth analysis on Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Metabolic Disorders, Ophthalmology and Oncology under development targeting Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)

The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics and enlists all their major and minor projects

The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Alteogen Inc

CSL Ltd

Eli Lilly and Co

Formycon AG

Regeneron Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Overview 6

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 10

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics Assessment 12

Assessment by Mechanism of Action 12

Assessment by Route of Administration 13

Assessment by Molecule Type 15

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Companies Involved in Therapeutics Development 17

Alteogen Inc 17

CSL Ltd 17

Eli Lilly and Co 17

Formycon AG 18

Regeneron Pharmaceuticals Inc 18

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Drug Profiles 20

(aflibercept + nesvacumab) - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

aflibercept - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

aflibercept biosimilar - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

aflibercept biosimilar - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

CSL-346 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

ziv-aflibercept - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Dormant Products 43

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Discontinued Products 44

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Product Development Milestones 45

Featured News & Press Releases 45

Sep 22, 2017: NICE gives EYLEA the Green Light for Treating Visual Impairment Due to mCNV 45

Aug 30, 2017: Bayer to showcase latest Ophthalmology research at EURETINA 2017 45

May 09, 2017: The first UK trial comparing intravitreal aflibercept and laser for proliferative diabetic retinopathy reports at ARVO 2017 47

Feb 10, 2017: Study Published in Cell Metabolism shows Potential New Therapy for Diabetic Kidney Disease 48

Dec 01, 2016: CSL Commits to New Phase I Clinical Trials of CSL346 in Australia 49

Sep 28, 2016: Patients with BRVO, a sight threatening eye condition, now have first-line access to EYLEA (aflibercept solution for injection) on the NHS 50

Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists’ guidance 51

May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection 52

Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven 52

Feb 29, 2016: Formycon discloses details on second pipeline product - FYB203 is a biosimilar for Eylea (aflibercept) 53

Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization 54

Sep 25, 2015: Bayer’s Eye Drug Recommended for EU Approval in Fifth Indication 54

Sep 18, 2015: Three-Year Results with EYLEA Show Sustained Improvement in Vision for People with Diabetic Macular Edema 54

Jul 21, 2015: NICE gives green light to aflibercept solution for treating serious eye condition 55

Jun 26, 2015: Bayer Receives Approval for EYLEA for the Treatment of Retinal Vein Occlusion in Japan 56

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Products under Development by Companies, H2 2017 11

Number of Products by Stage and Mechanism of Actions, H2 2017 12

Number of Products by Stage and Route of Administration, H2 2017 14

Number of Products by Stage and Molecule Type, H2 2017 16

Pipeline by Alteogen Inc, H2 2017 17

Pipeline by CSL Ltd, H2 2017 17

Pipeline by Eli Lilly and Co, H2 2017 18

Pipeline by Formycon AG, H2 2017 18

Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 19

Dormant Projects, H2 2017 43

Discontinued Products, H2 2017 44

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Stage and Mechanism of Actions, H2 2017 12

Number of Products by Routes of Administration, H2 2017 13

Number of Products by Stage and Routes of Administration, H2 2017 13

Number of Products by Molecule Types, H2 2017 15

Number of Products by Stage and Molecule Types, H2 2017 15

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports